SEC Comment Letter 0000000000-23-007072 to DiaMedica Therapeutics Inc. (DMAC)
DiaMedica Therapeutics Inc.
Date: July 5, 2023 · CIK: 0001401040 · Accession: 0000000000-23-007072
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273068
Letter
United States securities and exchange commission logo July 5, 2023 Rick Pauls President and Chief Executive Officer DiaMedica Therapeutics Inc. 301 Carlson Parkway, Suite 210 Minneapolis, Minnesota 55305 Re:DiaMedica Therapeutics Inc. Registration Statement on Form S-3 Filed June 30, 2023 File No. 333-273068 Dear Rick Pauls: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Amy Culbert
Show Raw Text
United States securities and exchange commission logo
July 5, 2023
Rick Pauls
President and Chief Executive Officer
DiaMedica Therapeutics Inc.
301 Carlson Parkway, Suite 210
Minneapolis, Minnesota 55305
Re:DiaMedica Therapeutics Inc.
Registration Statement on Form S-3
Filed June 30, 2023
File No. 333-273068
Dear Rick Pauls:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Amy Culbert